182 related articles for article (PubMed ID: 35608860)
1. Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016: A Systematic Review.
Shen C; Tannenbaum D; Horn R; Rogers J; Eng C; Zhou S; Johnson B; Kopetz S; Morris V; Overman M; Parseghian C; Chang GJ; Lopez-Olivo MA; Kanwal R; Ellis LM; Dasari A
JAMA Netw Open; 2022 May; 5(5):e2213588. PubMed ID: 35608860
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer.
Goel S; Negassa A; Acuna-Villaorduna A
JAMA Netw Open; 2021 Dec; 4(12):e2136378. PubMed ID: 34910154
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
5. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database.
Shi Q; de Gramont A; Grothey A; Zalcberg J; Chibaudel B; Schmoll HJ; Seymour MT; Adams R; Saltz L; Goldberg RM; Punt CJ; Douillard JY; Hoff PM; Hecht JR; Hurwitz H; Díaz-Rubio E; Porschen R; Tebbutt NC; Fuchs C; Souglakos J; Falcone A; Tournigand C; Kabbinavar FF; Heinemann V; Van Cutsem E; Bokemeyer C; Buyse M; Sargent DJ
J Clin Oncol; 2015 Jan; 33(1):22-8. PubMed ID: 25385741
[TBL] [Abstract][Full Text] [Related]
6. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Mettu NB; Ou FS; Zemla TJ; Halfdanarson TR; Lenz HJ; Breakstone RA; Boland PM; Crysler OV; Wu C; Nixon AB; Bolch E; Niedzwiecki D; Elsing A; Hurwitz HI; Fakih MG; Bekaii-Saab T
JAMA Netw Open; 2022 Feb; 5(2):e2149040. PubMed ID: 35179586
[TBL] [Abstract][Full Text] [Related]
8. Colorectal Cancer Survival Gains and Novel Treatment Regimens: A Systematic Review and Analysis.
Jawed I; Wilkerson J; Prasad V; Duffy AG; Fojo T
JAMA Oncol; 2015 Sep; 1(6):787-95. PubMed ID: 26181239
[TBL] [Abstract][Full Text] [Related]
9. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
10. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
11. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
12. Oral versus intravenous fluoropyrimidines for colorectal cancer.
Chionh F; Lau D; Yeung Y; Price T; Tebbutt N
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD008398. PubMed ID: 28752564
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
14. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
15. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial.
Ng K; Nimeiri HS; McCleary NJ; Abrams TA; Yurgelun MB; Cleary JM; Rubinson DA; Schrag D; Miksad R; Bullock AJ; Allen J; Zuckerman D; Chan E; Chan JA; Wolpin BM; Constantine M; Weckstein DJ; Faggen MA; Thomas CA; Kournioti C; Yuan C; Ganser C; Wilkinson B; Mackintosh C; Zheng H; Hollis BW; Meyerhardt JA; Fuchs CS
JAMA; 2019 Apr; 321(14):1370-1379. PubMed ID: 30964527
[TBL] [Abstract][Full Text] [Related]
16. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Avallone A; Piccirillo MC; Nasti G; Rosati G; Carlomagno C; Di Gennaro E; Romano C; Tatangelo F; Granata V; Cassata A; Silvestro L; De Stefano A; Aloj L; Vicario V; Nappi A; Leone A; Bilancia D; Arenare L; Petrillo A; Lastoria S; Gallo C; Botti G; Delrio P; Izzo F; Perrone F; Budillon A
JAMA Netw Open; 2021 Jul; 4(7):e2118475. PubMed ID: 34309665
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
19. Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis.
Cremolini C; Antoniotti C; Pietrantonio F; Berenato R; Tampellini M; Baratelli C; Salvatore L; Marmorino F; Borelli B; Nichetti F; Bironzo P; Sonetto C; Bartolomeo MD; Braud F; Loupakis F; Falcone A; Di Maio M
Cancer Res Treat; 2017 Jul; 49(3):834-845. PubMed ID: 27857020
[TBL] [Abstract][Full Text] [Related]
20. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
